Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) jumped more than 29% on Friday that it had a loss and top Wall Street’s anticipations, and top the revenue anticipation. The revenue top is a optimistic sign to shareholders seeking high growth out of the firm.
The adjusted earnings a share surged to $-0.01 in the quarter against EPS of $-0.32 in the year-before quarter.
The revenue surged 303.64 percent to $8.88M from the year-earlier quarter.
Progenics Pharmaceuticals Inc. declared adjusted EPS loss of $0.01 a share. By that measure, the firm tops the mean analyst anticipates of $-0.31. It hammers the average revenue anticipates of $1.16M.
Moving readers toward the broader market, let’s consider percentage change in stocks prices of other stocks in the similar sector who contribute major role in the market that includes Gilead Sciences, Inc. (NASDAQ:GILD) lost -1.55%, Geron Corporation (NASDAQ:GERN) edged down -9.60%, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) which also decreased -0.99% and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) closed up +3.31%.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stock’s trade at beginning with a price of $3.60 and throughout the trading session climbed at a high of $4.94 other than when day-trade ended the stock finally advanced +28.99% to $4.36.
The stock is going forward its 52 week low with 209.22% and lagging behind from its 52 week high price with -61.55%. PGNX last month stock price volatility remained 8.68%.
PGNX stock institutional ownership remained 84.37% while insider ownership included 0.36%. In its share capital PGNX has 44.88 million outstanding shares among them 43.04 million shares have been floated in market exchange.
Company’s beta coefficient included 1.27. Beta factors measures the amount of market risk associated with market trade.
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here